Get the Stockscreener App
12.21
0.41%
-0.05
After Hours:
12.21
Kazia Therapeutics Limited Adr stock is traded at $12.21, with a volume of 173.79K.
It is down -0.41% in the last 24 hours and down -14.14% over the past month.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
See More
Previous Close:
$12.26
Open:
$12.66
24h Volume:
173.79K
Relative Volume:
0.83
Market Cap:
$139.52M
Revenue:
$26,600
Net Income/Loss:
$-14.73M
P/E Ratio:
-1.79
EPS:
-6.8211
Net Cash Flow:
$-8.76M
1W Performance:
-9.89%
1M Performance:
-14.14%
6M Performance:
+70.77%
1Y Performance:
+24.34%
1-Day Range:
$12.04
$12.91
1-Week Range:
$12.03
$14.69
52-Week Range:
$4.86
$17.40
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Name
Kazia Therapeutics Limited Adr
Sector
Industry
Phone
01161298780088
Address
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Compare KZIA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
12.21 | 140.09M | 26,600 | -14.73M | -8.76M | -6.8211 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Laidlaw | Buy |
| Feb-06-25 | Initiated | Maxim Group | Buy |
| Oct-14-21 | Initiated | Maxim Group | Buy |
| Jan-05-21 | Initiated | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr Stock (KZIA) Latest News
KZIA|Kazia Therapeutics Ltd|Price:12.802|Chg%:+0.542 - TradingKey
Kazia Therapeutics (KZIA) grants director 100,000 stock options - Stock Titan
KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant - Stock Titan
Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance - Stock Titan
Kazia Therapeutics (KZIA) director awarded 100,000 ADS stock options - Stock Titan
Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director - Stock Titan
Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78 - Stock Titan
BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com - Investing.com Nigeria
Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA) - TradingView
Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO - Stock Titan
ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks - TradingView
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Kazia Therapeutics (KZIA) Surges 13.88% as Biotech Momentum AcceleratesHot Stock Picks - DonanımHaber
KZIA News | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) director details existing ADS option grants - Stock Titan
Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth - The Globe and Mail
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 232,956 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 95,110 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO - Stock Titan
KZIAKazia Therapeutics Limited ADR Options - Finviz
Kazia Therapeutics (NASDAQ: KZIA) holder reports 18.5% stake in ADS - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Phase 1b trial, enrollment to 36 patients - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Paxalisib Phase 1b, files prospectus - Stock Titan
Kazia (NASDAQ: KZIA) expands Phase 1b, registers 266,666 ADSs - Stock Titan
Paxalisib breast cancer trial triples size at Kazia (NASDAQ: KZIA) - Stock Titan
Kazia expands paxalisib trial enrollment to 36 patients in TNBC - Investing.com
KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) Chief Scientific Officer Sudha Rao files initial Form 3 - Stock Titan
KZIA | Kazia Therapeutics Limited American Insider Trading - Quiver Quantitative
KZIA SEC FilingsKazia Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform - Insider Monkey
Kazia (NASDAQ: KZIA) outlines cancer pipeline and runway to 2029 - Stock Titan
Dr. Sudha Rao joins Kazia Therapeutics (NASDAQ: KZIA) as part-time CSO - Stock Titan
Laidlaw initiates Kazia Therapeutics stock coverage with buy rating - Investing.com
Kazia Therapeutics Expands Oncology Pipeline With SETDB1 Targeted Epigenetic Platform - BioPharma APAC
Kazia Therapeutics (NASDAQ: KZIA) in-licenses SETDB1 platform, pays $1.39M - Stock Titan
Kazia (NASDAQ: KZIA) licenses SETDB1 platform, plans $6M dual-program push - Stock Titan
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Bitget
Kazia adds AI-built cancer drug platform with lead candidate MSETC - Stock Titan
Kazia Therapeutics (KZIA) CEO updates ADS option exercise price details - Stock Titan
Kazia Therapeutics (KZIA) executive discloses multiple stock option positions - Stock Titan
95,110 ADS supplement and director exit — Kazia (NASDAQ: KZIA) - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) holder reports 1.59M ADS; 13.90% stake - Stock Titan
Alumni Capital exits KZIA holdings (KZIA) — 0 ADS as of Jan 30, 2026 - Stock Titan
Kazia Therapeutics (KZIA) widens loss yet amasses $69.5m cash and new ATM - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADSs, reports $69.46M cash - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADSs; posts half‑year update - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) files prospectus supplement for 232,956 ADSs - Stock Titan
Kazia Therapeutics (KZIA) raises major cash despite $12.6m loss - Stock Titan
Kazia Therapeutics Limited Adr Stock (KZIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):